Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10624068			
Filing Date		2003-07-21			
First Named Inventor	Willer	n L. Repko			
Art Unit		2616			
Examiner Name	Hong Soi Cho				
Attamen Desket Number		23344			

				Allom	ey Doc	ket Number	23341				
					U.S.I	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue C	Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	6101195	A	2000-08	1-08	Lyons et al.					
If you wish	to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Pate of cited Docu	Rele		es,Columns,Lines where vant Passages or Relevant res Appear		
	1										
If you wish	n to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d butto	n. Add		_
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages of Figures App	vant or Relevant	-
	1	11088314	JP		A	1999-03-30	Samoff Corp.				
	2	2003060649	JP		A	2003-02-28	NTT Corp.				
If you wish	n to a	dd additional Foreign P	atent Do	cument	citation	information pl	Lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_

#### Application Number 10624068 Filing Date 2003-07-21 INFORMATION DISCLOSURE First Named Inventor Willem I Renko STATEMENT BY APPLICANT Art Unit 2616 ( Not for submission under 37 CFR 1.99) Evaminor Namo Hong Sol Cho Attorney Docket Number

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs
	1		

23341

If you wish to add additional non-patent literature document citation information please click the Add button Add

### EXAMINER SIGNATURE Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10624068		
Filing Date		2003-07-21		
First Named Inventor	Willer	Villem L. Repko		
Art Unit		2616		
Examiner Name	Hong	Sol Cho		
Attorney Docket Number		23341		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication \( \overline{\text{If form a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, on learn of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(40.)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/leljr/	Date (YYYY-MM-DD)	2007-04-16
Name/Print	Lawrence E. Laubscher, Jr.	Registration Number	28233

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Department of Commence, P. 0 Box 1449, Alexandri, V.S. 2211-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, V.S. 22131-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultural or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultural or patient. If you do not furnish the requested more primarily to the process and the process and the process and the patient of the patient of

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.